Actos Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status...
The firm is currently investigating Actos bladder cancer lawsuits on behalf of individuals treated with the type 2 diabetes drug.(PRWeb February 07, 2013)Read the full story at http://www.prweb.com/releases/actos-lawsuits/actos-bladder-cancer/prweb10410339.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 9, 2013 Category: Pharmaceuticals Source Type: news
Actos Lawsuit News: Bernstein Liebhard LLP Comments on Decline in...
The firm is currently investigating Actos lawsuits on behalf of patients who developed bladder cancer, allegedly due to their use of the type 2 diabetes drug.(PRWeb February 05, 2013)Read the full story at http://www.prweb.com/releases/actos-lawsuits/actos-bladder-cancer/prweb10400727.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 7, 2013 Category: Pharmaceuticals Source Type: news
US Drug Watchdog Now Urges All Diabetics Nationwide Who Used the...
The US Drug Watchdog says, "We fear there are thousands of diabetics in the United States, who used the diabetes drug called Actos, then developed bladder cancer, and never connected the dots...(PRWeb February 06, 2013)Read the full story at http://www.prweb.com/releases/2013/2/prweb10386627.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 7, 2013 Category: Pharmaceuticals Source Type: news
US Drug Watchdog Now Urges Diabetics Who Used the Diabetes Drug Actos...
The US Drug Watchdog now fears that most diabetics who took the diabetes drug called Actos, and then developed bladder cancer would never consider the possibility that the bladder cancer, and this...(PRWeb February 04, 2013)Read the full story at http://www.prweb.com/releases/2013/2/prweb10386430.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 5, 2013 Category: Pharmaceuticals Source Type: news
FDA Triple Play Against Type 2 Diabetes
A fourth dipetidyl peptidase-4 inhibitor is approved as monotherapy and in combinations with metformin and pioglitazone. (Source: Consultant Live)
Source: Consultant Live - February 4, 2013 Category: Primary Care Source Type: news
New Actos Bladder Cancer Lawsuit: Now, AttorneyOne Can Provide Advice
According to court documents, on December 18th, 2012, a Florida resident filed a lawsuit in Louisiana Western District Court alleging he suffered bladder cancer from Actos. In light of these news,...(PRWeb February 01, 2013)Read the full story at http://www.prweb.com/releases/2013/2/prweb10383083.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 1, 2013 Category: Pharmaceuticals Source Type: news
US Drug Watchdog Now Urges Family Members Of Diabetics Who Used the...
The US Drug Watchdog says, "We seriously doubt few of the nearly 26 million US diabetics would ever consider the use of a diabetes drug called Actos possibly contributing to bladder cancer, but...(PRWeb January 30, 2013)Read the full story at http://www.prweb.com/releases/2013/1/prweb10359681.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 30, 2013 Category: Pharmaceuticals Source Type: news
Takeda Receives FDA Approval For Three New Type 2 Diabetes Therapies, NESINA (Alogliptin) And Fixed-Dose Combinations OSENI (Alogliptin And Pioglitazone) And KAZANO (Alogliptin And Metformin HCl)
Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda PharmaceuticalsU.S.A., Inc. today announced thatthe United States(U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - January 29, 2013 Category: Pharmaceuticals Source Type: news
US Drug Watchdog is Now Urging Bladder Cancer Victims to Call the...
The US Drug Watchdog is now urging diabetics who used the diabetes drug called Actos to call the Johnson Law Group if prior to the diagnosis they had been using this diabetes drug. For more...(PRWeb January 28, 2013)Read the full story at http://www.prweb.com/releases/2013/1/prweb10359434.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 28, 2013 Category: Pharmaceuticals Source Type: news
FDA approves alogliptin for type 2 diabetes as three separate preparations
Source: FDA
Area: News
The FDA has approved alogliptin for the treatment of type 2 diabetes as three separate preparations: alogliptin monotherapy; alogliptin in combination with metformin; and alogliptin in combination with pioglitazone.
Alogliptin stimulates insulin release following meals and was shown to be safe and effective as monotherapy in 14 clinical trials involving approximately 8,500 patients with type 2 diabetes. Alogliptin monotherapy reduced glycosylated haemoglobin (HBA1c) by 0.4 to 0.6% compared to placebo following 26 weeks of treatment.
The FDA has requested additional dat...
Source: NeLM - News - January 28, 2013 Category: Drugs & Pharmacology Source Type: news
Three Type 2 Diabetes Pills From Takeda Approved By FDA
Nesina (alogliptin) tablets, Oseni (alogliptin and pioglitazone) tablets, and Kazano (alogliptin and metformin hydrochloride) tablets, for the treatment of type 2 diabetes, for use along with diet and exercise, have been approved by the Food and Drug Administration. They are designed to improve blood sugar control. The active ingredients pioglitazone and metformin hydrochloride are already approved by the FDA for type 2 diabetes management - Alogliptin is new... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 27, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news
Takeda Receives FDA Approval for Oseni (alogliptin and pioglitazone) for Type 2 Diabetes
DEERFIELD, Ill. and OSAKA, Japan, Jan. 25, 2013 /PRNewswire/ --
Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned
subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced
that the United States (U.S.) Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 26, 2013 Category: Drugs & Pharmacology Source Type: news
US Drug Watchdog Now Urges Any Diabetic Who Used The Diabetes Drug...
The US Drug Watchdog says, "Actos users who developed bladder cancer have incredibly horrific stories, many lives have been destroyed, and we fear many lives have been lost, and most diabetics...(PRWeb January 25, 2013)Read the full story at http://www.prweb.com/releases/2013/1/prweb10333449.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 26, 2013 Category: Pharmaceuticals Source Type: news
FDA Licenses Diabetes Drug Alogliptin, in 3 FormulationsFDA Licenses Diabetes Drug Alogliptin, in 3 Formulations
The new dipeptidyl peptidase IV inhibitor was approved as monotherapy, and in fixed-dose combinations with metformin and pioglitazone. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 26, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA approves three new drug treatments for type 2 diabetes
The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 25, 2013 Category: American Health Source Type: news
